Literature DB >> 32770770

Efficacy of fiberoptic bronchoscopy and bronchoalveolar lavage in childhood-onset, complicated plastic bronchitis.

Li Wang1, Wang Wang1, Jing-Min Sun1, Shen-Wang Ni2, Jun-Li Ding1, Yu-Lin Zhu1, Sheng-Gang Ding1.   

Abstract

BACKGROUND: Plastic bronchitis (PB) is a rare, variable, and potentially fatal disease. This study aimed to assess the efficacy of fiberoptic bronchoscopy (FOB) and bronchoalveolar lavage (BAL) in treating children with PB.
METHODS: In total, 15 children with PB, between 2012 and 2020, were enrolled in our study. Within 12 hours of admission, FOB and BAL were performed and reviewed under local anesthesia and sedation. Before and after FOB, clinical findings and chest imaging were evaluated.
RESULTS: Regarding the onset of symptoms before FOB, all cases had prominent cough for 7.00 ± 4.55 days, and 14 had persistent high fever. In total, 13 cases had complete obstruction from bronchial casts, consistent with consolidated lesions; 2 had partial airway obstruction. Within 3 days, complete resolution was revealed in nine cases. Overall, six cases underwent repeated FOB (range, 2-3 times) for persistent atelectasis and airway obstruction. Except for two cases with type 2 PB, cast histology confirmed type 1 PB for all cases. Only eight children had minor intra- and post-procedure complications. Reverse transcription-polymerase chain reaction for Mycoplasma pneumoniae in sputum and BAL samples were positive in 13 cases. Next-generation sequencing of the BAL samples was positive for adenovirus and Human parainfluenza virus in one case, respectively. During 1 month to 7 years of follow-up, no patient developed PB recurrence, asthmatic attacks, or chronic cough.
CONCLUSIONS: Early FOB and BAL were effective in alleviating clinical findings, atelectasis, and airway obstruction. Serial FOB could be performed in patients with recurrent symptoms.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  bronchial casts; children; consolidation; obstruction; recurrence

Year:  2020        PMID: 32770770     DOI: 10.1002/ppul.25016

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

1.  High Expression of MUC5AC, MUC5B, and Layilin Plays an Essential Role in Prediction in the Development of Plastic Bronchitis Caused by MPP.

Authors:  Yu Ma; Yeqi Gu; Xinxing Zhang; Wenjing Gu; Ting Wang; Huiming Sun; Yinfang Dai; Yongdong Yan; Yuqing Wang; Meijuan Wang; Huiquan Sun; Chuangli Hao; Liping Fan; Zhengrong Chen
Journal:  Front Microbiol       Date:  2022-06-13       Impact factor: 6.064

2.  Individualized Analysis and Treatment of Difficult Weaning From Ventilation Following Open Cardiac Surgery in Young Children With Congenital Heart Disease.

Authors:  Xiaoming Wu; Jinlan Chen; Chukwuemeka Daniel Iroegbu; Jian Liu; Ming Wu; Xia Xie; Kun Xiang; Xun Wu; Wangping Chen; Peng Huang; Wenwu Zhou; Chengming Fan; Jinfu Yang
Journal:  Front Cardiovasc Med       Date:  2022-06-01

3.  Effect of bronchofiberscopic lavage with budesonide suspension on refractory mycoplasma pneumoniae pneumonia.

Authors:  Ya Li; Wei Yang; Xin Wu; Xiaohua Gou
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

4.  Bronchoscopic interventions for plastic bronchitis in children without structural heart disease.

Authors:  Erin F Kallam; Ajay S Kasi; Rucha Patki; George Lucas Silva; Dawn M Simon; Shelley Caltharp; Lokesh Guglani
Journal:  Eur J Pediatr       Date:  2021-06-23       Impact factor: 3.183

5.  Development and validation of a nomogram to predict plastic bronchitis in children with refractory Mycoplasma pneumoniae pneumonia.

Authors:  Lihua Zhao; Tongqiang Zhang; Xiaojian Cui; Linsheng Zhao; Jiafeng Zheng; Jing Ning; Yongsheng Xu; Chunquan Cai
Journal:  BMC Pulm Med       Date:  2022-06-27       Impact factor: 3.320

6.  Interleukin-6 in blood and bronchoalveolar lavage fluid of hospitalized children with community-acquired pneumonia.

Authors:  Yun Zhang; Wenyu Zheng; Haonan Ning; Jing Liu; Fuhai Li; Xiuli Ju
Journal:  Front Pediatr       Date:  2022-09-08       Impact factor: 3.569

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.